Indian stock news
On August 6, 2026, Neuland Laboratories Limited reported an exceptional financial performance for the first quarter of FY27, featuring a 975% year--on--year surge in net profit to ₹147.4 crore.
Financial & Operational Highlights:
- Revenue Growth: Total revenue more than doubled during the quarter, driven by robust sales in the Custom Manufacturing Solutions (CMS) and Generic Drug Substances (GDS) verticals.
- Margin Expansion: EBITDA witnessed a significant jump of 448%, reflecting improved product mix and operational efficiencies.
- Market Reaction: Following the announcement, the company's shares rose by over 6% on the Bombay Stock Exchange, as investors reacted to the strong commercial product pipeline.